CIK 0001761612 · Non-accelerated filer<br>Smaller reporting company
BICYCLE THERAPEUTICS PLC
Sign in to watch- Ticker
- BCYC
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- United Kingdom
- Entity type
- operating
- Phone
- 011441223261503
- Business address
- BLOCKS A & B, PORTWAY BUILDING, GRANTA PARK, GREAT ABINGTON, CAMBRIDGE, United Kingdom, CB21 6GS
- Former names
- BICYCLE THERAPEUTICS Ltd
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $64,039
- in 7 filings, $7K under 10b5-1 plans
Net −$64,039. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Lee Kevin −$27K CHIEF EXECUTIVE OFFICER sold 1% of stake
- Swanton Robert Charles −$12K Director sold 18% of stake
- Skynner Michael −$9K CHIEF SCIENTIFIC OFFICER sold 2% of stake
- Perry Jennifer Scott −$7K Chief Operating Officer sold 2% of stake
- Hannay Michael Charles Ferguson −$6K CHIEF PROD & SUPPLY CHAIN OFF sold 2% of stake
Reading 60 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-01-03 | Kalowski Lee President and CFO | Grant or award · Employee Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2022-01-03 | Gutierrez-Ramos Jose-Carlos Director | Grant or award | +5,000 | 5,000 | ||
| 2022-01-03 | Gutierrez-Ramos Jose-Carlos Director | Grant or award · Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2022-01-03 | Crockett Nigel Chief Business Officer | Grant or award | +15,000 | 15,000 | ||
| 2022-01-03 | Crockett Nigel Chief Business Officer | Grant or award · Employee Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2022-01-03 | Bourque Janice Director | Grant or award | +5,000 | 5,000 | ||
| 2022-01-03 | Bourque Janice Director | Grant or award · Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2022-01-03 | Milnes Alistair Chief Operating Officer | Grant or award | +15,000 | 15,000 | ||
| 2022-01-03 | Milnes Alistair Chief Operating Officer | Grant or award · Employee Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2021-12-22 | Legault Pierre Director | Option exercise | +97,860 | $8.48 | $830K | 97,860 |
| 2021-12-22 | Legault Pierre Director | Sale | −97,860 | $58.01 | $5.7M | 0 |
| 2021-12-22 | Legault Pierre Director | Option exercise · Stock Option (Right to Buy) | −97,860 | 23,312 | ||
| 2021-12-21 | Keen Nicholas Chief Scientific Officer | Option exercise | +15,477 | $14.00 | $217K | 15,477 |
| 2021-12-21 | Keen Nicholas Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) | −15,477 | 161,927 | ||
| 2021-12-21 | Legault Pierre Director | Option exercise | +44,537 | $8.44 | $376K | 44,537 |
| 2021-12-21 | Legault Pierre Director | Sale | −44,537 | $57.11 | $2.5M | 0 |
| 2021-12-21 | Legault Pierre Director | Option exercise · Stock Option (Right to Buy) | −44,537 | 121,172 | ||
| 2021-12-20 | Legault Pierre Director | Option exercise | +7,603 | $8.41 | $64K | 7,603 |
| 2021-12-20 | Legault Pierre Director | Sale | −7,603 | $57.02 | $434K | 0 |
| 2021-12-20 | Legault Pierre Director | Option exercise · Stock Option (Right to Buy) | −7,603 | 165,709 |
Page 18 of 26 · 520 trades